Evaluation of the usefulness of anti-cholinergic and B(Beta)3 agonist in patients with OAB.

Trial Profile

Evaluation of the usefulness of anti-cholinergic and B(Beta)3 agonist in patients with OAB.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2016

At a glance

  • Drugs Imidafenacin (Primary) ; Mirabegron (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms SORT
  • Most Recent Events

    • 11 Oct 2012 New trial record
    • 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top